Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
- 20 March 2015
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (9), 975-977
- https://doi.org/10.1200/jco.2014.59.8433
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid CancerJournal of Clinical Oncology, 2015
- NSCLC and HER2: Between Lights and ShadowsJournal of Thoracic Oncology, 2014
- Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRASFrontiers in Oncology, 2014
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFRNature, 2012
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- BRAFMutations in Hairy-Cell LeukemiaNew England Journal of Medicine, 2011
- Crizotinib — Latest Champion in the Cancer Wars?New England Journal of Medicine, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004